IL2 and amyotrophic lateral sclerosis: CD4+ and CD8+ T cells of healthy individuals and ALS patients were treated with IL-2, IL-2 + anti-CD3/28 mAbs, or IL-2 + sAJ2 before they were used in ELISA (Figure 4a–c), or in ELISpot (Figure 4d,e).